

Reviewed at UC Davis by Dr. Cheema

Abatacept (Orencia)

JCODE: J0129

OFFICE ADMINISTRATION

Indications for Prior Authorization

Moderate to Severe active Rheumatoid Arthritis

Juvenile Idiopathic Arthritis (age 6-17)

Patients must meet the following criteria for the indications above:

Rheumatoid Arthritis

1. Diagnosis of moderate to severe active rheumatoid arthritis by Rheumatologist (the prescribing MD does not have to be a rheumatologist)

and

2. Inadequate response to one or more Disease Modifying Anti-Rheumatic Drugs (DMARDs): Auranofin (Ridaura), Azathioprine (Imuran), Gold sodium thiomalate (Aurolate), Hydroxychloroquine (Plaquenil, Methotrexate (Rheumatrex), D-penicillamine (Cuprimine), Sulfasalazine (Azulfidine).

and

Inadequate response to at least one TNF antagonist: etanercept (Enbrel), infliximab (Remicade), or adalimumab (Humira).

Juvenile Idiopathic Arthritis

1. Diagnosis of active Juvenile Idiopathic Arthritis in patients 6-17 years old confirmed by a rheumatologist

and

2. Inadequate response to one or more Disease Modifying Anti-Rheumatic Drugs (DMARDs): Auranofin (Ridaura), Azathioprine (Imuran), Gold sodium thiomalate (Aurolate), Hydroxychloroquine (Plaquenil, Methotrexate (Rheumatrex), D-penicillamine (Cuprimine), Sulfasalazine (Azulfidine).

or

Documented medical justification why methotrexate and sulfasalazine cannot be used.

and

3. Inadequate response to at least one TNF antagonist: etanercept (Enbrel), infliximab (Remicade), or adalimumab (Humira).

The following indications do not meet the criteria for use established by the Western Health Advantage Pharmacy and Therapeutics Committee.

Crohn's Disease

Ulcerative Colitis

Psoriasis

Psoriatic Arthritis

Irritable Bowel Disease

Abatacept should not be given concomitantly with a TNF antagonist or anakinra.